Is Tafinlar generic?

Tafinlar is the trade name for the generic chemotherapy drug dabrafenib. In some cases, health care professionals may use the generic name dabrafenib when referring to the trade name Tafinlar. Drug type: Tafinlar is a targeted therapy.

How long does Tafinlar and Mekinist work?

Of the 22 untreated patients who had a response with TAFINLAR + MEKINIST, 59% had a duration of response of 6 months or longer before their disease got worse. The median (or midpoint) duration of response for patients who were previously treated was 12.6 months.

Who makes Tafinlar?

TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) | Official Site from Novartis.

Is Selumetinib FDA approved?

On April 10, 2020, the FDA approved selumetinib (KOSELUGO, AstraZeneca) for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.

What type of drug is Tafinlar?

Enzyme inhibitor

Can Mekinist be cut?

Swallow Mekinist tablets whole. Do not crush or dissolve tablets. Do not change your dose or stop Mekinist unless your health care provider tells you to.

What are the side effects of Tafinlar?

Common side effects of TAFINLAR and MEKINIST in people with NSCLC include:

  • Fever.
  • Fatigue.
  • Nausea.
  • Vomiting.
  • Diarrhea.
  • Dry skin.
  • Decreased appetite.
  • Rash.

Is Dabrafenib and trametinib chemotherapy?

Dabrafenib and trametinib are chemotherapy drugs taken to shrink lung cancer cells and decrease symptoms from lung cancer.

When to take Tafinlar with or without Mekinist?

The incidence and severity of pyrexia increase when TAFINLAR is administered with MEKINIST. Withhold TAFINLAR for temperature of ≥101.3ºF or fever complicated by hypotension, rigors or chills, dehydration, or renal failure, and evaluate for signs and symptoms of infection.

Which is better for melanoma Mekinist or Tafinlar?

TAFINLAR ® (dabrafenib) capsules, in combination with MEKINIST ® (trametinib) tablets, is indicated: for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test

When to discontinue Tafinlar in NSCLC patients?

Limitations of Use: TAFINLAR is not indicated for the treatment of patients with wild-type BRAF melanoma, NSCLC, or ATC. New Primary Malignancies, Cutaneous and Noncutaneous. Perform dermatologic evaluations prior to initiation of therapy, every 2 months while on therapy, and for up to 6 months following discontinuation of the combination.

What are the symptoms of uveitis with Tafinlar?

Uveitis (including iritis and iridocyclitis) can occur with TAFINLAR. Perform ophthalmologic evaluation for any visual disturbances. Monitor patients for visual signs and symptoms of uveitis (eg, change in vision, photophobia, and eye pain).